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Validity of International Association for the Study of Lung
Cancer Proposals for the Revision of N Descriptors
in Lung Cancer
Jin Gu Lee, MD,* Chang Young Lee, MD,* Mi Kyung Bae, MD,* In Kyu Park, MD,*
Dae Joon Kim, MD,* Kil Dong Kim, MD,† and Kyung Young Chung, MD*
Objective: This study was conducted to assess the validity of the
pending suggestions for N descriptors by the International Association
for the Study of Lung Cancer.
Methods: Medical records from 1032 patients with non-small cell
lung cancer who had pulmonary resection and proven stage I–III
were retrospectively reviewed. Lymph node stations were grouped
together into six “zones”: peripheral or hilar for N1 and upper or
lower mediastinal, aortopulmonary, and subcarinal for N2. Survival
was analyzed according to the proposed subdividing N descriptors:
single-zone N1 (N1a), multizone N1 (N1b), single-zone N2 (N2a),
and multizone N2 (N2b).
Results: The 5-year survival rate was 63.8% for N0, 42.3% for N1a,
36.5% for N1b, 35.8% for N2a, and 17.4% for N2b. There were
three distinct prognostic groups for N1 and N2 nodes: N1a, N1b or
N2a, and N2b disease. In multivariate analysis, age, sex, type of
surgery, T stage, and node status were independent prognostic
factors. Hazard ratios versus N0 for N1a, N1b or N2b, N2b, and N3
were 1.577, 2.164, 3.291, and 5.897, respectively.
Conclusion: Amalgamating lymph node stations into zones and
subdividing N descriptors described a significant stepwise deterio-
ration of disease status. Although more studies are needed, the
lymph node zone and subdivided N descriptors could be one of step
for desirable approach of forthcoming tumor, node, metastasis
classification in non-small cell lung cancer.
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Since the lung cancer staging system was first developed in1973,1 lymph node involvement has been categorized as
N0 (no nodes involved), N1 (regional nodes involved), N2
(ipsilateral mediastinal nodes involved), or N3 (contralateral
mediastinal or supraclavicular nodes involved). The classifi-
cation of these N descriptors into the overall tumor stages of
I through III has been used to predict outcomes and assist in
treatment selection. During the past 20 years, numerous
studies have evaluated the validity of the N descriptors and
suggested that they could be refined to provide more accurate
prognostic stratification by subdividing them either according
to specific anatomic locations or the number of involved
lymph nodes.2–5 Recently, the International Association for
the Study of Lung Cancer (IASLC) has proposed significant
modifications to the existing tumor, node, metastasis (TNM)
and stage grouping classifications, affecting T and M descrip-
tors.6–9 They found value in grouping lymph node stations
into six “zones”: peripheral or hilar for N1, and upper or
lower mediastinal, aortopulmonary, and subcarinal for N2.
Nevertheless, they have concluded that the current N descriptor
should be maintained in the non-small cell lung cancer
(NSCLC) staging system because there were insufficient data to
determine whether the N descriptors should be subdivided.7
In the present study, we focused on their proposed
lymph node zones and subdivisions of distinct prognostic
groups (N zone descriptor). We analyzed prognosis according
to their suggestions, validating the value of the N zone
descriptor in predicting prognosis in patients with NSCLC.
METHODS
Patients
We reviewed the records of 1346 patients with NSCLC
who underwent pulmonary resection at our institute from
January 1990 to December 2005. Patients with pathologic
stage I–III were included in this study. Patients who received
preoperative induction therapy and those who died within 1
month after surgery were excluded. Patients were also ex-
cluded if their histology was other than squamous, adenocar-
cinoma, large cell, NSCLC, and adenosquamous. Ultimately,
a total of 1032 patients were evaluated. Pathologic staging
was based on the 1997 TNM classification system.10 Lymph
node status was assessed according to the system defined by
Mountain and Dresler.11 Lymph node stations were grouped
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together into six zones according to the proposal by the
IASLC7: Lymph nodes at levels 1 through 4 were grouped
together into the upper zone, levels 5 and 6 into the aorto-
pulmonary zone, level 7 into subcarinal zone, levels 8 and 9
into the lower zone, levels 10 and 11 into the hilar zone, and
levels 12 to 14 into the peripheral zone. Survival was ana-
lyzed according to the proposed subdivided N zone descrip-
tors: single-zone N1 (N1a), multizone N1 (N1b), single-zone
N2 (N2a), and multizone N2 (N2b). Lobectomy and system-
atic lymph node dissection were the procedures of choice
regardless of clinical stage. All patients were followed either
until death or the last follow-up date (December 1, 2007). The
Institutional Review Board of Yonsei University College of
Medicine approved this retrospective study. The need for
individual consent of patients whose records were evaluated
was waived because individuals were not identified within the
study.
Statistical Analysis
The association between variables was analyzed by
either a 2 or t test. The duration of survival was defined as
the interval between the date of surgery and either the date of
death or the last follow-up date. The differences in survival
among groups were examined using a log-rank test, and
multivariate analyses were performed by means of the Cox
proportional hazard model in variables that had p-values of
less than 0.05 in the univariate analyses. Age, sex, type of
surgery, T stage, node status, and histologic type were se-
lected for potential prognostic factors. A p value of less than
0.05 was considered significant. The data were analyzed
using SPSS for Windows (Statistical Package for Social
Science, SPSS Inc., Chicago, IL).
RESULTS
The 1032 patients included 226 female and 806 male
patients, with a median age of 62 years (range, 28–81 years).
The median follow-up time was 35.8 months (range, 1.0–
214.4 months). All patient characteristics are summarized in
Table 1. The mean number of examined lymph nodes was
29.7  12.5 (31.6  12. in right side and 27.1  11.7 in left
side). The mean number of explored lymph node zone was
4.7  0.6 (4.7  0.6 in right side and 4.7  0.7 in left side).
There were 171 patients for N1a, 23 for N1b, 193 for N2a,
and 91 for N2b. The relationship between N zone descriptors
and lymph node zone is described in Table 2. The overall
5-year survival rate of all 1032 patients was 49.4%. The
5-year survival rate was 63.8% for pN0, 42.2% for pN1,
29.4% for pN2, and 0% for pN3 (p  0.001, Figure 1).
Survival was analyzed according to N zone descriptors. The
5-year survival rate was 63.8% for N0, 42.3% for N1a, 36.5%
for N1b, 35.8% for N2a, 17.4% for N2b, and 0% for N3
(Figure 2). There were three distinct prognostic groups for N1
and N2 nodes: N1a, N1b or N2a, and N2b disease. The
survival differences between the groups were significant (N1a
versus N1b or N2a, p  0.043; N1b orN2a versus N2b, p 
0.001; Figure 3). In multivariate analysis, age, sex, type of
surgery, T stage, and subdivided nodes status were indepen-
dent prognostic factors. Hazard ratios versus N0 for N1a, N1b
or N2a, N2b, and N3 were 1.577, 2.164, 3.291, and 5.897
respectively (Table 3).
Comment
Our results indicate that the IASLC suggestion of
amalgamating lymph node stations into zones and subdivid-
TABLE 1. Clinical and Pathologic Patient Characteristics
Variables No. of Patients (%)
Age
62 yr 508 (49.2)
62 yr 524 (50.8)
Sex
Male 806 (78.1)
Female 226 (21.9)
Type of resection
Pneumonectomy 387 (37.5)
Bilobectomy 129 (12.5)
Lobectomy 513 (49.7)
Wedge resection 3 (0.3)
Histologic subtype
Squamous cell carcinoma 542 (52.5)
Adenocarcinoma 399 (38.7)
Large cell 54 (5.2)
Non-small cell lung cancer 2 (0.2)
Adenosquamous 35 (3.4)
Pathologic tumor factor (pT)
pT1 187 (18.1)
pT2 615 (59.6)
pT3 165 (16.0)
pT4 65 (6.3)
Pathologic node factor (pN)
pN0 542 (52.5)
pN1 194 (18.8)
pN2 284 (27.5)
pN3 12 (1.2)
Pathologic stage
IA 129 (12.5)
IB 331 (32.1)
IIA 30 (2.9)
IIB 175 (17.0)
IIIA 290 (28.1)
IIIB 77 (7.5)
TABLE 2. Relationship between N Zone Descriptors and
Lymph Node Zone
N Zone
Descriptors n
Lymph Node “Zones”
H P U L S AP
N1a 171 104 67 — — — —
N1b 23 23 23 — — — —
N2a 193 88 52 88 14 54 37
N2b 91 57 28 76 20 78 30
H, hilar (levels 10 and 11); P, peripheral (levels 12–14); U, upper mediastinal
(levels 1–4); L, lower mediastinal (levels 8 and 9); S, subcarinal (level 7); AP,
aortopulmonary (levels 5 and 6).
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ing N zone descriptors describes a significant stepwise dete-
rioration in disease status. The N zone descriptor was an
independent prognostic factor in our multivariate analysis.
Based on these results, N zone descriptors provide a more
accurate prognostic stratification than the N descriptor in the
current TNM staging system.
The IASLC has prepared revisions for the seventh
edition of the TNM classification and proposed significant
modifications to the existing T and M descriptors in TNM
staging for lung cancer.6–9 In their exploratory analyses for
the N descriptors, three groups based on lymph node zones
were found to have significantly different survival rates:
patients who had single-zone N1 (N1a), those who had either
multiple N1 (N1b) or single N2 zone (N2a), and those who
had multiple N2 zone (N2b) metastases. These distinct prog-
nostic groups suggested that it might be appropriate to sub-
divide the current N staging descriptors into N1a, N1b or
N2a, and N2b, but the IASLC concluded that the current N
descriptors should be maintained in the NSCLC staging
system because there were insufficient data to determine
whether the N descriptors should be subdivided.7 Despite
their decision, we focused on the proposed approach of
grouping lymph node zones and subdividing distinct prog-
nostic groups because we felt it had the potential to solve the
problems of the current TNM staging system for lung cancer.
The current TNM staging system for NSCLC has
served us well for a number of years, and has helped us
design treatment plans and discuss patient prognosis. Never-
theless, the most complex and unsatisfactory aspect of the
current TNM staging system is the method for assessing
nodal disease. The current nodal system can result in different
prognoses even in the same nodal stage, especially with
mediastinal (N2) lymph node involvement. Several subclas-
sifications have been proposed to provide more accurate
prognostic stratification by subdividing either according to
specific anatomic locations or the number of involved lymph
nodes.2–5 Furthermore, the current N descriptors are only
anatomically based. Disease burden of the lymph nodes is
also important in the prognostic outcome of malignancies. In
the latest TNM classification, disease burden of lymph nodes
is included in the definition (as the number of the metastatic
lymph nodes) of the N descriptor in breast, gastric, and
colorectal cancer, and these N descriptors show significant
correlation with prognosis.12–16 But in the current TNM
staging for lung cancer, only the anatomic extent of lymph
node metastases defines the N descriptors. The significance of
FIGURE 1. Overall survival curves for patients according to pN status (5YSR: 5-year survival rate).
The number of patients at risk at the indicated time
pN0 542 453 313 230 157 108 70
pN1 194 129 81 58 41 31 17
pN2 284 149 85 64 38 25 14
pN3 12 3 1 0 0 0 0
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the number of lymph node metastases has also been sug-
gested in NSCLC.17,18 One additional problem of the current
lymph node system is the ambiguity of the anatomic border.19
When there is no clear anatomic separation between nodal
stations, as it happens with nodal stations 2 and 4, in this
particular case, the boundaries of the Mountain-Dresler map
are not practical at mediastinoscopy or at thoracotomy. More-
over, the fat pad containing the pretracheal lymph nodes must
be dissected en block because there is no distinction or
anatomic separation between the nodal stations. The same
occurs with stations 5 and 6, whose separating structure, the
ligamentum arteriosum, cannot be identified on chest radiog-
raphy, on computed tomography scan, at mediastinoscopy, or
at extended cervical mediastinoscopy. Accordingly, the def-
inition of the current lymph node system has been challenged.
Considering these problems, grouping lymph node
zone and subdividing groups (N zone descriptors) have sev-
eral benefits. First, N zone descriptors provide more accurate
prognostic stratification for patients with NSCLC compared
with the current N descriptors. Second, N zone descriptors are
defined according both to anatomic location and disease
burden of the lymph nodes, and lymph node disease burden
shows significant correlation with prognosis. Third, N zone
descriptors make it easier to indicate the location of the
lymph node zone compared with the used lymph node sta-
tions. Fourth, this easier anatomic localization is also appli-
cable in the clinical setting. Identification of the boundaries
between lymph node stations is difficult in chest computed
tomography or positron emission tomography scans because
it is based on anatomic structure. With the N zone descriptors,
localization of the lymph node zone is easier to identify.
Finally, the N zone descriptor is simple to learn and apply.
Nevertheless, N zone descriptors have some limita-
tions. First, even though N zone descriptors are easily indi-
cated in clinical and pathologic settings, some ambiguity of
anatomic boundaries remain, especially in lymph node sta-
tions 7, 8, and 10, which are included in the subcarinal zone,
lower zone, and hilar zone, respectively. The area below the
carina and the main bronchi almost invariably contains a
cluster of nodes. There are no anatomic landmarks separating
stations 7, 8, and 10. The N zone descriptors succeed to the
ambiguity. Second, patients with N1b were grouped together
with those with N2a in the zone descriptors because the
5-year survival rate of N1b was similar to that of N2a. We
observed that the 10-year survival rate of N1b (29.2%) was
closer to N1a (28.7%) than to N2a (21.3%) in our study, and
FIGURE 2. Overall survival curves for patients according to N zone descriptors (5YSR: 5-year survival rate).
The number of patients at risk at the indicated time
N1a 171 115 73 51 35 26 14
N1b 23 14 7 6 6 5 0
N2a 193 113 70 53 29 20 10
N2b 91 36 16 12 9 5 3
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data from the IASLC7 showed a similar survival curve with
long-term follow-up. These differences may be due to the
comparatively small number of patients in N1b (23 patients in
our study, and 173 patients in the IASLC data). Additional
analysis with a larger population is warranted.
Our patient population did not allow us to analyze each
proposed N zone in relationship to each proposed T stage,
i.e., T1aN1a versus T1aN1b versus T2aN1a, etc. This would
require a larger number of patients. This analysis could not be
done in the IASLC database, either, and this was the main
reason why the findings on nodal zones could not become
recommendations for changes in the new edition of the TNM
classification for lung cancer.
Lymph node involvement is one of the most important
prognostic factors in NSCLC. The insufficient collection of
lymph node data compared with the data for T descriptors in
the IASLC analysis was probably due to the complexity and
difficulty of describing lymph nodes and the disagreed con-
sensus for mediastinal lymph node dissection in NSCLC
surgery. We are convinced that the inclusion of lymph node
zones is important for predicting patient prognosis and argue
that additional effort to collect sufficient supportive data
TABLE 3. Multivariate Analysis Including N Zone
Descriptors
Variables
Hazard
Ratio
95% Confidence
Interval p
Age (yr)
Age 62/age 62 1.644 1.385–1.952 0.001
Sex
Male/female 1.310 1.046–1.640 0.019
Operation
Pneumonectomy 1.358 1.133–1.628 0.001
Other procedure
T stage
T1 1 Reference
T2 1.665 1.262–2.197 0.001
T3 2.475 1.800–3.404 0.001
T4 3.303 2.256–4.836 0.001
N zone descriptor
N0 1 Reference
N1a 1.577 1.243–2.000 0.001
N1b or N2a 2.164 1.750–2.676 0.001
N2b 3.291 2.489–4.353 0.001
N3 5.897 3.254–10.688 0.001
FIGURE 3. Overall survival curves for patients according to grouped N zone descriptors (5YSR: 5-year survival rate).
The number of patients at risk at the indicated time
N1a 171 115 73 51 35 26 14
N1b or N2a 216 127 77 59 35 25 13
N2b 91 36 16 12 9 5 3
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worldwide is necessary for the forthcoming TNM classifica-
tion for lung cancer.
In conclusion, amalgamating lymph node stations into zones
and subdividing N descriptors as suggested by the IASLC describes
a significant stepwise deterioration in disease status. Although more
studies are needed, the lymph node zone and subdivided N descrip-
tors could be one of step for desirable approach of forthcoming
TNM classification in NSCLC.
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